Fingerprint
Dive into the research topics of 'Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
Silwan Chedid, Edgardo Rivera, Debbie K. Frye, Nuhad Ibrahim, Francisco Esteva, Vicente Valero, Gabriel Hortobagyi, Karl L. Mettinger, Massimo Cristofanilli
Research output: Contribution to journal › Article › peer-review
4
Scopus
citations